Experienced in Myelofibrosis

Dr. Carlos R. Bachier

Hematology | Oncology
Methodist Physician Practices PLLC
7700 Floyd Curl Dr, 
San Antonio, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
34 Years of Experience
Experienced in Myelofibrosis
Methodist Physician Practices PLLC
7700 Floyd Curl Dr, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carlos Bachier is a Hematologist and an Oncologist in San Antonio, Texas. Dr. Bachier has been practicing medicine for over 34 years and is rated as an Experienced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bachier is currently accepting new patients.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Puerto Rico School Of Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in PR
Hospital Affiliations
Methodist Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
MMM Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Plan De Salud Menonita
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

METHODIST PHYSICIAN PRACTICES PLLC
7700 Floyd Curl Dr, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Drug: Allogeneic NKG2D-Targeted CAR-Natural Killer T Cells
Study Phase: Phase 1
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Combination product
Study Drugs: CLBR001 CAR-T Cells, SWI019
Study Phase: Phase 1
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 2/Phase 3
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Biological
Study Drug: Mana 312
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
View 11 Less Clinical Trials

24 Total Publications

Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma.
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma.
Journal: Transplantation and cellular therapy
Published: September 23, 2024
Similar Doctors
Elite in Myelofibrosis
Dr. Robyn M. Scherber
Hematology
Elite in Myelofibrosis
Dr. Robyn M. Scherber
Hematology
7979 Wurzbach Rd, 
San Antonio, TX 
 (0.6 miles away)
210-450-1406
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robyn Scherber is a Hematologist in San Antonio, Texas. Dr. Scherber is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Myeloproliferative Neoplasms (MPN), Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, and Bone Marrow Transplant. Dr. Scherber is currently accepting new patients.

Distinguished in Myelofibrosis
Dr. Usha S. Perepu
Hematology Oncology | Hematology | Oncology
Distinguished in Myelofibrosis
Dr. Usha S. Perepu
Hematology Oncology | Hematology | Oncology

The University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (0.6 miles away)
210-450-9000
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Usha Perepu is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Perepu is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Von Willebrand Disease (VWD), Myeloproliferative Neoplasms (MPN), Heyde Syndrome, Bone Marrow Aspiration, and Splenectomy. Dr. Perepu is currently accepting new patients.

Experienced in Myelofibrosis
Dr. Anand B. Karnad
Oncology | Hematology
Experienced in Myelofibrosis
Dr. Anand B. Karnad
Oncology | Hematology

The University Of Texas Health Science Center At San Antonio

7703 Floyd Curl Dr, Suite Mc7977, 
San Antonio, TX 
 (0.3 miles away)
210-450-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anand Karnad is an Oncologist and a Hematologist in San Antonio, Texas. Dr. Karnad is rated as an Advanced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Thrombocytopenia, Large-Cell Immunoblastic Lymphoma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Karnad is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bachier's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 12 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile